Login to Your Account



CHINA’S STROKE RATE IS HIGHEST

Neuralstem doses ischemic stroke patient with stem cells directly into the brain

By Shannon Ellis
Staff Writer

Wednesday, February 5, 2014

SHANGHAI – Neuralstem Inc. has dosed its first patient with NSI-566 stem cells, commencing the Phase I/II trial in China for ischemic stroke.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription